Skip to main content

Table 2 Image and clinical symptoms for PCa monitoring

From: Data-driven translational prostate cancer research: from biomarker discovery to clinical decision

Name

Type

Description

PMID

Image features

 Zinc-Specific iCEST MRI

Diagnosis

Differentiating normal and malignant prostate cells with a high fold-change

31430007

 DCE-MRI

Prognosis

Reflecting PCa microcirculation and showing correlation with PSA and clinical stage

30327584

 DWI signal

Prognosis

Providing information for bone metastasis and treatment of mCRPC

28906339

 DWI signal

Therapy

Monitoring changes in response to androgen deprivation therapy in PCa patients

25415730

 FLT PET/CT

Therapy

Predicting progression-free survival and promoting immunotherapy for mPCa patients

30700328

 PSMA-derived volumetric parameters

Therapy

Evaluating whole-body tumor burden and facilitating therapy monitoring for mPCa

28522740

 BSI

Prognosis

Predicting the survival time of mCRPC patients treated with Abiraterone Acetate

28723520

 aBSI

Prognosis

Predicting the overall survival of patients with mCRPC

29799999

 BSI, ΔBSI

Prognosis

Predicting poor overall survival and cancer specific survival

29137438

Clinical symptoms

 Lower urinary tract symptoms

Diagnosis

The symptoms increase the attention of physicians for PCa diagnosis

23313032

 Lower urinary tract symptoms

Therapy

The changes are associated with the responses to salvage radiotherapy for biochemical recurrence of PCa

25991382

 Urinary problems, fatigue

Therapy

Predicting health-related quality of life in PCa patients with localized radiation therapy

30263893

 Sexual dysfunction

Therapy

This symptom may be caused by the therapy of M0-CRPC

28285412

 Depression

Therapy

The severity is positively correlated with the duration of androgen deprivation therapy

30651026

  1. PCa prostate cancer, mPCa metastatic prostate cancer, mCRPC metastatic castration resistant prostate cancer, iCEST ion chemical exchange saturation transfer, MRI magnetic resonance imaging, DCE dynamic contrast-enhanced, DWI diffusion-weighted imaging, FLT 3′-Deoxy-3′-18F-fluorothymidine, PET positron emission tomography, CT computed tomography, PSMA prostate-specific membrane antigen, BSI bone scan index, aBSI automated, BSI: ΔBSI elevated BSI change on treatment, PMID PubMed ID